Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Sangamo Therapeutics Community
NasdaqCM:SGMO Community
1
Narratives
written by author
1
Comments
on narratives written by author
23
Fair Values set
on narratives written by author
Create a narrative
Sangamo Therapeutics
Popular
Undervalued
Overvalued
Community Investing Ideas
Sangamo Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Neurology IND And Fabry Agreements Will Transform Treatment
Key Takeaways Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements. Cost reduction initiatives and a clear path to accelerated approval for treatments may lead to improved net margins and early revenue generation.
View narrative
US$5.00
FV
90.8% undervalued
intrinsic discount
20.84%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
13
users have followed this narrative
1 day ago
author updated this narrative
Your Valuation for
SGMO
SGMO
Sangamo Therapeutics
Your Fair Value
US$
Current Price
US$0.46
85.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-328m
355m
2015
2018
2021
2024
2025
2027
2030
Revenue US$355.4m
Earnings US$68.7m
Advanced
Set Fair Value